Gilead Sciences (GILD) Rating Reiterated
In analysts note shared with investors on Thursday, 8 February, Gilead Sciences (GILD) stock had its Buy Rating reiterated by equity analysts at Citigroup. They currently have a $105.0 price target on company. Citigroup’s target gives a potential upside of 34.24 % from the company’s last stock close.
GILD is currently trading 0.00% lower at $0.00 as of 2:04 PM New York time. Gilead Sciences’s stock is 0% over the last 200 days. It has underperformed the S&P 500, which has risen 6.00% over the same time period.
According to data compiled by Thomson Reuters, Gilead Sciences (GILD)’s stock is covered by 19 equity analysts across the Street, with 0 analysts giving it a Sell rating, 16 a Buy rating, while 9 consider it a Hold. The 12-month consensus target price for the stock is $111.05, which reflects an upside potential of ∞% over the current price.
Domini Social Investments Llc had the largest stake with ownership of 4,906 shares as of Q2 2015 for 17.99% of the long stock exposure. Cabot is another quite bullish investment manager who is having 147,130 shares of Gilead Sciences or 9.41% of their long stock exposure. In addition, Hollow Brook Wealth Management Llc have 8.91% of their long stock exposure invested in the company for 190,499 shares. The Singapore-based fund Temasek Holdings (Private) Ltd disclosed it had bought a stake worth about 8.86% of the investment manager’s stock portfolio in Gilead Sciences. The Massachusetts-based fund Tekla Capital Management Llc is also positive about the stock, possessing 13.83M shares or 8.09% of their long stock exposure.
Gilead Sciences (GILD) closed at $0 yesterday. A total of shares of the company’s stock traded hands. This is down from average of shares. Gilead Sciences has a 52 week low of $0.00 and a 52 week high of $0. The company has a market cap of $ and a P/E ratio of 0.
Get the latest Gilead Sciences (GILD) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
The post Citigroup Keeps $105.0 Price Target On Gilead Sciences (GILD), Keeps Buy Rating appeared first on Octafinance.